Eslicarbazepine acetate

CNS Drugs

Volumn 23, Issue 1, 2009, Pages 71-79

  McCormack, Paul L ^a,b   Robinson, Dean M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug profiles; Antiepileptic drugs, therapeutic use; Epilepsy, treatment; Eslicarbazepine, adverse reactions; Eslicarbazepine, pharmacodynamics; Eslicarbazepine, pharmacokinetics; Eslicarbazepine, therapeutic use; Partial seizures, treatment

Indexed keywords

BIA 2 005; CARBAMAZEPINE; CLONAZEPAM; CYTOCHROME P450 2C9; DIGOXIN; DRUG METABOLITE; ESLICARBAZEPINE ACETATE; ETHINYLESTRADIOL; ETIRACETAM; GLUCURONOSYLTRANSFERASE 1A1; LAMOTRIGINE; LEVONORGESTREL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; TOLBUTAMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; WARFARIN; ZEBINIX;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; CLINICAL TRIAL; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG WITHDRAWAL; FOCAL EPILEPSY; HEADACHE; HUMAN; KIDNEY CLEARANCE; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VERTIGO; VOMITING;

ANIMALS; DIBENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSIES, PARTIAL; HUMANS; SODIUM CHANNEL BLOCKERS;

EID: 57449108979     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200923010-00005     Document Type: Review

References (29)

1. World Health Organization. Epilepsy: aetiology, epidemiology and prognosis [online]. Available from URL: http://www.who.int/mediacentre/ factsheets/fs165/en/ [Accessed 2008 Oct 13]
2. Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001 Jul; 42 Suppl. 3: 27-30
3. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007 Jan; 4 (1): 88-96
4. Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-digydro5H-dibenz[b,f]azepine-5- carboxamide derivatives. J Med Chem 1999 Jul 15; 42 (14): 2582-7
5. Bonifacio MJ, Sheridan RD, Parada A, et al. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001 May; 42: 600-8
6. Sierra-Paredes G, Oreiro-Garcia MT, Vazquez-Illanes MD, et al. Effect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus. Epilepsy Res 2007 Oct; 77 (1): 36-43
7. Ambrosio AF, Silva AP, Malva JO, et al. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001 May 15; 61: 1271-5
8. Ambrosio AF, Silva AP, Araujo I, et al. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 2000 Oct 13; 406: 191-201
9. Potschka H, Pekcec A, Soares-Da-Silva P. Inhibition of kindling progression by eslicarbazepine acetate and licarbazepine [abstract no. p071]. Epilepsia 2007 Oct; 48 Suppl. 7: 58-9
10. Sierra-Paredes G, Nunez-Rodriguez A, Vazquez-Lopez A, et al. Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. Epilepsy Res 2006 Dec; 72 (2-3): 140-6
11. Almeida L, Nunes T, Gutierrez MJ, et al. A randomized, double-blind, placebo- and moxifloxacin-controlled, 4 period crossover trial to evaluate the effects of eslicarbazepine acetate on cardiac repolarization in healthy subjects [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
12. Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004 Aug; 44 (8): 906-18
13. Almeida L, Falcao A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005 Sep; 45 (9): 1062-6
14. Falcao A, Maia J, Almeida L, et al. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007 Jul; 28 (5): 249-56
15. Maia J, Vaz-da-Silva M, Almeida L, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D 2005; 6 (4): 201-6
16. Nunes T, Maia J, Almeida L, et al. Pharmacokinetic interaction between eslicarbazepine acetate and lamotrigine in healthy subjects [abstract no. 3.248]. Epilepsia 2007 Oct; 48 Suppl. 6: 339-40
17. Almeida L, Falcao A, Maia J, et al. Steady-state pharmacokinetics of once-daily and twice-daily regimens of eslicarbazepine acetate (BIA 2-093) in healthy subjects [abstract no. 2.102]. Epilepsia 2006 Oct; 47 Suppl. 4: 154
18. Maia J, Almeida L, Vaz-da-Silva M, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics of digoxin in healthy subjects [abstract no. 2.261]. Epilepsia 2005 Oct 1; 46 Suppl. 8: 178-9
19. Perucca E, Falcão A, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with epilepsy [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
20. Maia J, Almeida L, Falcao A, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008 Mar; 46 (3): 119-30
21. Almeida L, Potgieter JH, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008 Mar; 64 (3): 267-73
22. Elger C, Halász P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
23. Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007 Mar; 48 (3): 497-504
24. Hufnagel A, Ben-Menachem E, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
25. Lopes-Lima J, Gil-Nagel A, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
26. Guekht A, Elger C, Halász P, et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate: results of a 1-year open-label extension study [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
27. Cramer J, Maia J, Almeida L, et al. Quality-of-life improvement esliduring long-term treatment with eslicarbazepine acetate [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
28. Hodoba D, Czlonkowska A, Cramer J, et al. Depressive symptoms improvement during long-term treatment with eslicarbazepine acetate [abstract plus poster]. 8th European Congress on Epileptology; 2008 Sep 21-25; Berlin
29. Fontes-Ribeiro C, Macedo T, Nunes T, et al. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D 2008; 9 (6): 447-54